Masimo (MASI) Expected to Announce Quarterly Earnings on Tuesday

Masimo (NASDAQ:MASI) is anticipated to issue its Q2 2025 quarterly earnings data after the market closes on Tuesday, August 5th. Analysts expect the company to announce earnings of $1.23 per share and revenue of $368.65 million for the quarter. Masimo has set its FY 2025 guidance at 5.300-5.600 EPS.

Masimo (NASDAQ:MASI) last posted its earnings results on Tuesday, May 6th. The medical equipment provider reported $1.36 earnings per share for the quarter, beating the consensus estimate of $1.24 by $0.12. Masimo had a positive return on equity of 22.56% and a negative net margin of 25.06%. The company had revenue of $372.00 million for the quarter, compared to analyst estimates of $367.79 million. During the same quarter in the prior year, the company earned $0.77 earnings per share. Masimo’s revenue was down 24.5% compared to the same quarter last year. On average, analysts expect Masimo to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

Masimo Trading Down 1.5%

Shares of MASI stock opened at $162.18 on Tuesday. Masimo has a fifty-two week low of $101.61 and a fifty-two week high of $194.88. The stock has a market cap of $8.79 billion, a P/E ratio of -17.69 and a beta of 1.19. The business has a fifty day simple moving average of $162.55 and a 200-day simple moving average of $165.63. The company has a quick ratio of 1.62, a current ratio of 2.17 and a debt-to-equity ratio of 0.67.

Insider Activity at Masimo

In related news, COO Bilal Muhsin sold 10,000 shares of the business’s stock in a transaction dated Monday, May 12th. The stock was sold at an average price of $163.28, for a total value of $1,632,800.00. Following the transaction, the chief operating officer owned 24,172 shares in the company, valued at approximately $3,946,804.16. The trade was a 29.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 16.90% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of MASI. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Masimo by 0.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 11,371 shares of the medical equipment provider’s stock worth $1,894,000 after buying an additional 66 shares in the last quarter. Dynamic Technology Lab Private Ltd bought a new position in Masimo in the 1st quarter worth approximately $220,000. Jones Financial Companies Lllp grew its holdings in Masimo by 1,267.1% in the 1st quarter. Jones Financial Companies Lllp now owns 2,201 shares of the medical equipment provider’s stock worth $367,000 after buying an additional 2,040 shares in the last quarter. AQR Capital Management LLC grew its holdings in Masimo by 136.5% in the 1st quarter. AQR Capital Management LLC now owns 8,142 shares of the medical equipment provider’s stock worth $1,305,000 after buying an additional 4,700 shares in the last quarter. Finally, Royal Bank of Canada grew its holdings in Masimo by 44.5% in the 1st quarter. Royal Bank of Canada now owns 43,884 shares of the medical equipment provider’s stock worth $7,311,000 after buying an additional 13,513 shares in the last quarter. Institutional investors and hedge funds own 85.96% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have weighed in on the company. Needham & Company LLC reissued a “hold” rating on shares of Masimo in a research report on Thursday, April 10th. Raymond James Financial dropped their price target on Masimo from $204.00 to $185.00 and set an “outperform” rating for the company in a research report on Wednesday, May 7th. Piper Sandler reissued an “overweight” rating and set a $200.00 price target (down previously from $215.00) on shares of Masimo in a research report on Wednesday, May 7th. BTIG Research reaffirmed a “buy” rating on shares of Masimo in a research report on Monday, July 14th. Finally, Wells Fargo & Company lowered their price objective on Masimo from $205.00 to $190.00 and set an “overweight” rating for the company in a research report on Wednesday, May 7th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat.com, Masimo has a consensus rating of “Moderate Buy” and an average target price of $191.60.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.